This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
PENELOPE-B was a randomized, parallel-group, quadruple-masked phase 3 trial of palbociclib versus placebo in addition to standard endocrine treatment for hormone receptor-positive, HER2-normal primary breast cancer in patients with residual disease after neoadjuvant chemotherapy and surgery. The registered primary endpoint was invasive disease-free survival (iDFS), a time-to-event endpoint assessed from randomization to the specified data cutoff.
| Feature | PENELOPE-B |
|---|---|
| Phase | Phase 3 |
| Condition | Breast Cancer; Hormonreceptor Positive; Her2-normal; Postneoadjuvant Treatment With CDK 4/6 Inhibitor; CPS-EG Score |
| Design | Randomized, parallel-group |
| Masking | Quadruple |
| Allocation | Randomized |
| Primary purpose | Treatment |
| Enrollment | 1250 |
| Interventions | Palbociclib PD-0332991; Placebo |
| Primary endpoint type | Time-to-event |
| Trial status | COMPLETED |
| Lead sponsor | GBG Forschungs GmbH |
| Sponsor type | OTHER |
| Start | 30 October 2013 |
| Primary completion | 24 August 2020 |
| ClinicalTrials.gov | NCT01864746 |
2. Clinical Question
The clinical question can be expressed as a randomized comparison of palbociclib added to standard endocrine treatment versus placebo added to standard endocrine treatment in the registered population: hormone receptor-positive, HER2-normal patients with residual disease after neoadjuvant chemotherapy and surgery.
Population
Patients with hormone receptor-positive, HER2-normal primary breast cancer who had residual disease after neoadjuvant chemotherapy and surgery, with the registry also identifying CPS-EG score as part of the condition description.
Intervention
Palbociclib (PD-0332991) in addition to standard endocrine treatment.
Comparator
Placebo in addition to standard endocrine treatment.
Primary question
Does the palbociclib strategy differ from the placebo strategy with respect to invasive disease-free survival?
3. Trial Design
Palbociclib strategy
- Palbociclib PD-0332991
- Standard endocrine treatment
Placebo strategy
- Placebo
- Standard endocrine treatment
The ClinicalTrials.gov record does not provide randomized arm sample sizes, allocation ratio, dosing schedule, treatment duration, or detailed eligibility criteria.
4. Endpoints
The registry identifies one primary endpoint, classified as a time-to-event outcome. Results are posted for the endpoint, but the ClinicalTrials.gov record contains no formal statistical-analysis records, effect estimates, confidence intervals, or p-values.
| Endpoint | Registry definition / time frame | Statistical type |
|---|---|---|
| Invasive Disease Free Survival (iDFS) | Invasive disease-free survival (iDFS) is defined according to Hudis (J Clin Oncol 2007) as the time period between randomization and first event, including ipsi- or contralateral invasive in-breast or loco-regional recurrence, distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause, invasive contralateral breast cancer, and second primary invasive cancer. Time frame: from date of randomisation to data cut off: 24 August 2020 (approximately 6 years and 6 months). | Time-to-event |
5. Statistical Methodology
Because the registered primary endpoint is a time-to-event measure, its analysis is fundamentally different from comparing a simple proportion at one fixed visit. Each participant can contribute information for a different amount of follow-up, and participants who have not experienced the event by the end of observation can contribute censored follow-up.
Kaplan-Meier estimation
A standard approach for an endpoint such as iDFS is the Kaplan-Meier estimator. It estimates the probability of remaining event-free over time while allowing participants to be censored at their last known event-free assessment.
Here, di represents events at event time ti, while ni represents the number at risk immediately before that time.
The registry data posted on ClinicalTrials.gov for PENELOPE-B do not report a Kaplan-Meier estimate, median iDFS, event count, survival probability at a specified time, or a Kaplan-Meier curve. Those quantities are therefore not presented as trial results here.
Log-rank comparison
For a randomized comparison of two time-to-event groups, a log-rank test is a conventional method for comparing the event-time distributions. It uses information across the follow-up period rather than reducing the outcome to whether each participant had experienced an event by a single fixed date.
Cox proportional-hazards model
A Cox proportional-hazards model is another standard approach for estimating a relative treatment effect for time-to-event data. Its effect measure is the hazard ratio.
This is a general interpretation of a hazard ratio, not a reported PENELOPE-B estimate. A hazard ratio is not the same as a risk ratio, an absolute risk difference, or a probability that an individual patient benefits.
Censoring
Time-to-event analyses require an explicit treatment of participants who have not experienced the event by the time their observation ends. Such observations are generally right-censored. Censoring allows available follow-up to contribute information without treating the absence of an observed event as equivalent to confirmed long-term event-free survival.
Confidence intervals
A confidence interval around a time-to-event effect estimate quantifies statistical uncertainty under the specified analysis framework. A narrow interval generally indicates greater precision than a wide interval, although precision and clinical importance are different concepts.
P-values
If a formal comparison were reported, its p-value would address the compatibility of the observed data with a specified null hypothesis under the statistical testing framework. A p-value is not a measure of effect size and does not describe the magnitude of clinical benefit.
6. Results
ClinicalTrials.gov reports that outcome results are posted for PENELOPE-B, including the registered primary endpoint. However, the posted statistical analyses contains no statistical-analysis records. Consequently, the available trial data do not provide a formal comparison estimate, confidence interval, or p-value for iDFS.
What analysis would normally be used?
For a randomized two-group trial with iDFS as a time-to-event endpoint, a conventional analysis would typically estimate the time-to-event distributions with Kaplan-Meier methods and compare the randomized groups with a time-to-event test such as the log-rank test. A Cox proportional-hazards model would commonly be used to estimate a hazard ratio and confidence interval.
Those methods describe the appropriate statistical framework for an endpoint of this type; they are not presented as the formal PENELOPE-B analysis because the ClinicalTrials.gov record does not report the corresponding statistical-analysis record.
Why no numerical treatment effect is shown
A statistical result is more than a treatment label and an endpoint name. To report an estimated treatment effect responsibly, the underlying result must include the actual estimate and its uncertainty, and ideally the analysis population and testing framework. Substituting an outside publication result would violate the source restriction for this page. The absence of a registry-reported estimate is therefore treated as missing evidence rather than an invitation to reconstruct a number from memory.
7. Safety Results
The ClinicalTrials.gov record reports serious adverse events by randomized arm as affected participants divided by participants at risk.
| Safety measure | Palbociclib | Placebo |
|---|---|---|
| Serious adverse events | 64/633 | 65/611 |
These figures describe the number affected and the corresponding number at risk for serious adverse events in each arm. They should not be treated as an efficacy endpoint or combined with iDFS into a single benefit-risk statistic.
The reported serious-adverse-event counts are numerically close in affected participants, with 64 reported in the palbociclib group and 65 in the placebo group. The denominators differ, however, so the raw counts alone are not a formal comparison of event rates. The ClinicalTrials.gov record does not provide a risk ratio, risk difference, confidence interval, p-value, event timing, or severity breakdown for these serious adverse events.
8. Statistical Methods Explained
Why is randomization important in PENELOPE-B?
Randomization assigns participants to the palbociclib or placebo strategy according to a study-level allocation mechanism rather than allowing treatment selection to be determined by individual clinical preference. This creates the basis for comparing outcomes between treatment groups while reducing systematic differences in measured and unmeasured baseline factors in expectation.
Why does quadruple masking matter?
The registry identifies PENELOPE-B as quadruple-masked. Masking can reduce opportunities for knowledge of treatment assignment to influence behavior, assessment, reporting, or other trial processes. For a time-to-event endpoint, masking is one component of the broader effort to preserve an unbiased comparison throughout follow-up.
Why is iDFS a time-to-event endpoint?
Invasive disease-free survival records not simply whether an event occurred, but the time from randomization until the first qualifying event. That distinction is important because two participants can both experience an event while having very different follow-up times. Time-to-event methods retain this temporal information.
Why can't the posted result be summarized with a hazard ratio here?
The ClinicalTrials.gov record say that results are posted, but they provide no entry in the statistical-analysis field. The page therefore distinguishes the existence of a posted outcome from the absence of a registry-reported formal statistical estimate.
What does a hazard ratio mean if one is reported?
A hazard ratio compares the estimated instantaneous event rates between treatment groups within a specified time-to-event model. A hazard ratio below one would indicate a lower estimated instantaneous event rate in the intervention group relative to the comparator under that model. It would not mean that the same percentage of participants experience a corresponding reduction in individual risk.
Why are confidence intervals important?
An effect estimate by itself gives only a point estimate. A confidence interval adds information about statistical precision. A wide interval indicates that substantially different effect sizes remain compatible with the data and model, whereas a narrower interval indicates greater precision. Neither width nor location of an interval alone determines clinical importance.
Why does the p-value not measure treatment effect size?
A p-value evaluates evidence against a specified null hypothesis within a particular statistical testing framework. It depends on both the magnitude of the observed difference and the amount of information in the data. Consequently, a small p-value does not by itself indicate a large treatment effect, and a larger p-value does not establish that two treatments have identical effects.
9. Interpreting the Primary Endpoint Carefully
The registered endpoint begins at randomization and follows participants until the first qualifying invasive disease-free survival event or the end of available observation. This makes iDFS a longitudinal endpoint rather than a single-visit measurement.
An iDFS endpoint does not, by itself, describe overall survival, quality of life, symptom burden, or every aspect of treatment safety. Each of those outcomes requires its own definition and analysis. The registry-reported PENELOPE-B data do not provide those additional numerical results.
The registered primary endpoint is assessed from randomization to the 24 August 2020 data cutoff, described in the ClinicalTrials.gov record as approximately 6 years and 6 months. A time-to-event estimate is therefore inseparable from its follow-up period and censoring framework.
Time-to-event results can change as additional events and follow-up accumulate. Keeping the data cutoff attached to the endpoint prevents results from different observation periods from being silently treated as one analysis.
10. Randomization and Masking as Statistical Design Features
The combination of randomized allocation, parallel-group design, and quadruple masking is statistically important because these are design features that precede the outcome analysis. They help determine how the treatment comparison is generated and how susceptible the study is to certain forms of systematic influence.
| Design feature | Role in interpretation |
|---|---|
| Randomized allocation | Provides the basis for a prospective comparison of the palbociclib and placebo strategies. |
| Parallel design | Maintains separate treatment strategies for the randomized groups rather than comparing sequential periods within the same participant. |
| Quadruple masking | Reduces opportunities for knowledge of treatment assignment to influence trial conduct or assessment. |
| Phase 3 | Places the study in a confirmatory clinical-development phase rather than an early exploratory phase. |
| Time-to-event primary endpoint | Requires analysis methods that account for follow-up time and censoring. |
These features do not guarantee that every possible source of bias is absent. They instead define the design framework within which the statistical evidence should be interpreted.
11. What the Registry Data Do Not Establish
A careful statistical analysis also requires identifying information that is not present in the ClinicalTrials.gov recordset. This prevents apparently precise conclusions from being created from incomplete evidence.
| Item | registry data | Interpretation |
|---|---|---|
| iDFS hazard ratio | Not reported | No numerical treatment-effect estimate is reported here. |
| iDFS confidence interval | Not reported | Precision of the formal effect estimate cannot be quantified from the ClinicalTrials.gov record. |
| iDFS p-value | Not reported | No formal hypothesis-test result is reproduced. |
| Median iDFS | Not reported | No median event-free time is reported here. |
| iDFS event counts | Not reported | No event-based numerical comparison is reconstructed. |
| Kaplan-Meier estimates | Not reported | No survival curve or time-specific iDFS estimate is reproduced. |
| Subgroup results | Not reported | No subgroup treatment-effect comparison is presented. |
| Baseline characteristics | Not reported | No baseline balance table is constructed. |
| Detailed statistical-analysis record | None reported | The formal analysis specification cannot be attributed to the ClinicalTrials.gov record. |
This distinction is especially important for clinical-trial pages. A missing number is not evidence for a null effect, and it is not evidence for a positive effect. It is simply a number that is not available in the registry record.
12. Limitations
- No formal statistical-analysis records reported: the dataset contains no formal statistical analyses, so numerical effect estimates and formal hypothesis-test results cannot be reported from the ClinicalTrials.gov record.
- Posted outcome versus posted analysis: ClinicalTrials.gov indicates that results are posted and that four outcome measures are available, but the ClinicalTrials.gov recordset does not provide the corresponding statistical-analysis records.
- Incomplete endpoint definition: the registry-reported iDFS definition ends partway through the description of a second primary invasive cancer. This page does not reconstruct the missing registry text.
- Limited safety information: only serious adverse events by arm are reported. Other adverse-event categories, timing, severity, discontinuations, and formal comparisons are not included.
- No subgroup information: the ClinicalTrials.gov record does not provide subgroup-specific estimates or interaction tests.
- No baseline table: demographic and clinical characteristics by randomized arm are not reported.
- No reconstruction from external publications: the analysis intentionally does not import numerical results from publications, even where those publications are linked to the trial record, because the page's numerical source rule is limited to the ClinicalTrials.gov record.
- Time-to-event interpretation: any formal iDFS analysis would depend on censoring rules, analysis population, event definitions, and model assumptions. Those details are not reported in the statistical-analysis field provided here.
13. Why This Trial Matters Statistically
PENELOPE-B is a useful teaching case because it demonstrates an important distinction in clinical-trial statistics: trial design information and endpoint definitions can be highly specific even when the statistical-analysis output available in a registry extract is incomplete.
| Concept | How it appears in PENELOPE-B |
|---|---|
| Randomization | The registry identifies the allocation as randomized. |
| Parallel-group design | The design model is registered as parallel. |
| Masking | The trial is registered as quadruple-masked. |
| Time-to-event analysis | The primary endpoint, iDFS, is classified as time-to-event. |
| Event definition | iDFS is defined from randomization to the first specified invasive disease-free survival event. |
| Censoring | A time-to-event framework requires follow-up and censoring information when participants do not experience an event during observation. |
| Statistical estimation | Kaplan-Meier and Cox methods are standard approaches for this endpoint type, although the ClinicalTrials.gov record does not identify a formal PENELOPE-B analysis record. |
| Statistical uncertainty | A formal treatment-effect estimate would ordinarily be accompanied by a confidence interval, but none is reported. |
| Safety interpretation | Serious adverse events are reported as affected/at-risk counts by randomized arm. |
| Data cutoff | The registered iDFS time frame ends at 24 August 2020. |
14. A Practical Statistical Reading of PENELOPE-B
When reading a trial such as PENELOPE-B, it is useful to proceed in a fixed order rather than beginning with a single result number.
Start with the estimand
Identify the population, randomized intervention and comparator, endpoint, and time origin. Here, the primary endpoint starts at randomization and is iDFS.
Then identify the design
Randomization, parallel allocation, and quadruple masking describe how the comparison was constructed before the outcome data were analyzed.
Then identify the event
For iDFS, the event is the first qualifying event specified by the registry definition rather than simply any single type of recurrence.
Then identify the analysis
For a time-to-event endpoint, Kaplan-Meier estimation, log-rank comparison, and Cox modeling are common analytical tools. The registry extract does not specify which formal analysis was used in PENELOPE-B.
This sequence prevents a common statistical error: treating an endpoint label as though it were already a complete statistical result. A valid treatment comparison requires the estimate, its uncertainty, the analysis population, and the inferential framework in addition to the endpoint definition.
15. Related Tutorials
Learn more about the methods used in this trial:
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: PENELOPE-B, NCT01864746.
- Linked PubMed record: PubMed 33793299.
- Linked PubMed record: PubMed 42025846.
- Linked PubMed record: PubMed 40209141.
Continue through Clinical Biostats
Use the related tutorials and statistical calculators to explore the design and time-to-event concepts that underlie randomized clinical-trial analysis.
18. Record Summary
PENELOPE-B is a completed randomized phase 3, parallel-group, quadruple-masked trial enrolling 1250 participants and comparing palbociclib PD-0332991 with placebo in addition to standard endocrine treatment in the registered hormone receptor-positive, HER2-normal breast cancer population with residual disease after neoadjuvant chemotherapy and surgery. Its registered primary endpoint is invasive disease-free survival, a time-to-event measure defined from randomization to the first qualifying event through the 24 August 2020 data cutoff.
The principal statistical lesson is methodological as much as numerical. The ClinicalTrials.gov record identifies the trial design, endpoint, time frame, and safety counts, but does not supply a formal statistical-analysis record for the primary endpoint. Therefore, this page describes the appropriate time-to-event analytical framework without substituting an external hazard ratio, confidence interval, or p-value for the missing registry analysis.